GenoFAB biofoundries revolutionize drug development.
GenoFAB biofoundries integrate engineering and data science to generate biological insights that accelerate drug development programs. Simple. Revolutionary.
By effectively combining software, equipment, processes, and personnel, GenoFAB provides turnkey biofoundries for maximizing high-throughput drug development. This revolutionary approach accelerates productivity, facilitates digital transformation, and ushers in new and innovative workforce development opportunities. Think it’s not a game-changer? Think again.
And we do it all without diluting your IP.
The Power of Performance. Unified. Configured. Optimized.
Our biofoundries are the critical infrastructure combining data science and automation to enable rapid prototyping — thereby enhancing collaboration and accelerating the design, production, and preclinical testing of biologic drugs. Nobody else does it the GenoFAB way. Because a faster, more streamlined drug development process bolsters your Return on Investment in R&D by intensely reducing costs, reducing time to market, and dramatically increasing revenue.
Proprietary lab operating system
Specialized tools for lab work
Defined rules for lab operations
Skilled talent managing R&D
We bring the biofoundry of the future to you. Now. So you can supercharge your product development pipeline.
An Industry in Dire Need of Change
GenoFAB recognizes that combining automation and data science is key to improving the reproducibility of drug development programs.
Annual U.S. Spending on Non-Reproducible
Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US $28,000,000,000 (US$28B) per year spent on preclinical research that is not reproducible — in the United States alone.
Source: PLOS: The Economics of Reproducibility in Preclinical Research
More than 70% of researchers have tried and failed to reproduce another scientist's experiments, and more than half have failed to reproduce their own experiments.
Source: Nature: More Than 1,500 Scientist Lift The Lid On Reproducibility
Why GenoFAB? Why Now?
Simply, because the pharmaceutical industry is facing an existential productivity crisis. We provide biofoundries that challenge the status quo.
Specifically, the ROI of pharmaceutical R&D investment is predicted to become negative after 2026 if the industry does not change its approach to drug development.
Source: Deloitte: Measuring The Return From Pharmaceutical Innovation
We make it easier and faster. Because if you’re not first, you’re last.
When it comes to intellectual property, time is of the essence. There is no consolation prize for being the second to file a patent application. By having GenoFAB design, build, and operate the biofoundry your drug development program needs, you will accelerate the production of reproducible data that will support stronger patent applications.
You need to be first. Our biofoundry technologies ensure you are.
The risks are all ours.
The IP is all yours.
GenoFAB was founded to mitigate the technical and human risks of building and operating a biofoundry. Because we have done it before. It’s what we know. It’s the intellectual property we bring to the table. Your expertise allows you to decide how to use these resources to develop new drug candidates. Allowing you to focus on what you know. While NOT diluting your IP.
Your team needs an engineering partner.
That partner is GenoFAB.